You are using the account as a guest user. You can also place your order directly without logging in or signing up.
by Naba Batool
11-01-2022The company has already started working on the jabs. This vaccination is being developed with the aim that it will provide the first line of defense against the new variant of concern ‘omicron’.
"This vaccine will be ready in March," he told CNBC's "Squawk Box". "We [are] already starting manufacturing some of these quantities at risk. "I don't know if we will need it. I don't know if and how it will be used."
Pfizer Inc Chief Executive Albert Bourla said on Monday that moving toward a redesigned COVID-19 vaccine that is specifically targeted to combat the Omicron variant of the coronavirus is the "most likely scenario." https://t.co/uaZUWHz1Y9
— Reuters Health (@Reuters_Health) January 10, 2022
He also went on to say that the existing and in-use routine of two vaccine shots and a booster jab has already led the groundwork for some reasonable protection against omicron. Yet a targeting vaccine that will focus entirely on omicron is the need of the hour. It will be a direct remedy for a strain that is not only contagious but is also causing serious symptoms in general masses.
Moderna CEO Stephane Bancel said in an interview with CNBC that the company is currently working to develop vaccinations that can prove to be effective against omicron and other sorts of emerging strains of this new year.
"We are discussing with public health leaders around the world to decide what we think is the best strategy for a potential booster for the fall of 2022," Bancel told the network.
"We need to be careful to try to stay ahead of a virus and not behind the virus."